Literature DB >> 23688258

GPER-1 expression decreases during breast cancer tumorigenesis.

Tanja Ignatov1, Christine Weißenborn, Angela Poehlmann, Antje Lemke, Andrzej Semczuk, Albert Roessner, Serban Dan Costa, Thomas Kalinski, Atanas Ignatov.   

Abstract

GPER-1 protein expression was immunohistochemically examined in 164 primary breast cancer specimens and their matched normal breast epithelium. GPER-1 down-regulation correlated significantly with increased histological grading (p = .015), lymph node metastases (p = .032), and negative estrogen receptor status (p = .018). The decrease of GPER-1 expression in breast cancer tissue, relative to normal tissue, was associated with poor overall survival (p = .043) and disease-free survival (p = .037) and remained a significant unfavorable factor in multivariate analysis for DFS (HR = 1.569; 95% CI, 1.024-2.797; p = .041) and OS (HR = 2.082; 95% CI, 1.248-4.773; p = .039). Thus aberrant GPER-1 expression seems to be an important factor in breast cancer progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23688258     DOI: 10.3109/07357907.2013.789901

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  19 in total

1.  GPER functions as a tumor suppressor in triple-negative breast cancer cells.

Authors:  Christine Weißenborn; Tanja Ignatov; Hans-Joachim Ochel; Serban Dan Costa; Ana Claudia Zenclussen; Zoya Ignatova; Atanas Ignatov
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-20       Impact factor: 4.553

2.  GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells.

Authors:  Christine Weißenborn; Tanja Ignatov; Angela Poehlmann; Anja K Wege; Serban D Costa; Ana Claudia Zenclussen; Atanas Ignatov
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-11       Impact factor: 4.553

Review 3.  GPER-novel membrane oestrogen receptor.

Authors:  Margaret A Zimmerman; Rebecca A Budish; Shreya Kashyap; Sarah H Lindsey
Journal:  Clin Sci (Lond)       Date:  2016-06-01       Impact factor: 6.124

Review 4.  Recent Advances on the Role of G Protein-Coupled Receptors in Hypoxia-Mediated Signaling.

Authors:  Rosamaria Lappano; Damiano Rigiracciolo; Paola De Marco; Silvia Avino; Anna Rita Cappello; Camillo Rosano; Marcello Maggiolini; Ernestina Marianna De Francesco
Journal:  AAPS J       Date:  2016-02-10       Impact factor: 4.009

Review 5.  International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators.

Authors:  Eric R Prossnitz; Jeffrey B Arterburn
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

6.  High neuronatin (NNAT) expression is associated with poor outcome in breast cancer.

Authors:  Norbert Nass; Sarah Walter; Dörthe Jechorek; Christine Weissenborn; Atanas Ignatov; Johannes Haybaeck; Saadettin Sel; Thomas Kalinski
Journal:  Virchows Arch       Date:  2017-05-24       Impact factor: 4.064

7.  Assessment of G Protein-Coupled Oestrogen Receptor Expression in Normal and Neoplastic Human Tissues Using a Novel Rabbit Monoclonal Antibody.

Authors:  Maria Bubb; Anna-Sophia Lieselott Beyer; Pooja Dasgupta; Daniel Kaemmerer; Jörg Sänger; Katja Evert; Ralph M Wirtz; Stefan Schulz; Amelie Lupp
Journal:  Int J Mol Sci       Date:  2022-05-06       Impact factor: 6.208

8.  Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-κB signals.

Authors:  Zhuo-Jia Chen; Wei Wei; Guan-Min Jiang; Hao Liu; Wei-Dong Wei; Xiangling Yang; Ying-Min Wu; Huanliang Liu; Chris K C Wong; Jun Du; Hong-Sheng Wang
Journal:  Mol Oncol       Date:  2016-01-18       Impact factor: 6.603

9.  G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth.

Authors:  Whitney K Petrie; Megan K Dennis; Chelin Hu; Donghai Dai; Jeffrey B Arterburn; Harriet O Smith; Helen J Hathaway; Eric R Prossnitz
Journal:  Obstet Gynecol Int       Date:  2013-11-27

10.  GPER-1 acts as a tumor suppressor in ovarian cancer.

Authors:  Tanja Ignatov; Saskia Modl; Maike Thulig; Christine Weißenborn; Oliver Treeck; Olaf Ortmann; Ac Zenclussen; Serban Dan Costa; Thomas Kalinski; Atanas Ignatov
Journal:  J Ovarian Res       Date:  2013-07-13       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.